Evidence map›Paper›PMID 40830295›Full record

ReviewStem cell reviews and reports2025

Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives.

Fanfei Liu, Qiqi Li, Yang Yang, Fang Lu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fanfei LiuDepartment of Ophthalmology, West China Hospital, Sichuan University, Guoxue xiang, No.37, Chengdu, Sichuan, 610041, China.
Qiqi LiState Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Ke-yuan Road 4, No. 1, Gao-peng Street, Chengdu, Sichuan, 610041, China.
Yang YangDepartment of Ophthalmology, West China Hospital, Sichuan University, Guoxue xiang, No.37, Chengdu, Sichuan, 610041, China. yang2012@scu.edu.cn.
Fang LuDepartment of Ophthalmology, West China Hospital, Sichuan University, Guoxue xiang, No.37, Chengdu, Sichuan, 610041, China. lufang@wchscu.cn.

Funding

1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University ZYYC23009National Key Research and Development Program of China 2023YFC3403300National Natural Science Foundation of China 82201210National Natural Science Foundation of China 82222030Postdoctor Research Fund of West China Hospital, Sichuan University 2024HXBH082Sichuan Science and Technology Program 2023NSFSC1660
6 · The paper itself

Abstract

Stem cell-based therapies hold promise for vision-threatening ocular diseases by promoting tissue repair and restoring visual function. Stem cells are classified by differentiation potential into two main types. Pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), possess the capacity to differentiate into somatic cells. Multipotent adult stem cells, such as mesenchymal stem cells (MSCs), are restricted to differentiating into cell types within specific lineages. The therapeutic potential of stem cells is discussed in the context of treating corneal diseases, glaucoma, and retinal disorders such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). This review focuses on the clinical trials of stem cell therapies for ocular diseases and discusses prospects in the field. Despite the considerable promise of these preclinical results in restoring visual function, significant challenges in clinical application remain, such as insufficient long-term cell survival, incomplete functional integration into host tissues, and the potential risk of oncogenic transformation. Future progress will depend on the development of standardized protocols, efficient delivery methods, and interdisciplinary collaboration to effectively translate preclinical advances into clinical applications.

Indexed as

Eye DiseasesStem Cell TransplantationAnimalsCell DifferentiationClinical Trials as TopicHumansMacular DegenerationClinical translationCorneal diseaseGlaucomaRetinal diseaseStem cell

Identifiers

PMID40830295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.